A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

• DOI: 10.1126/scitranslmed.aba7791
• Publication Date: 2021-09-15T18:06:04Z
• Authors: Eric S. Lightcap; Pengfei Yu; Stephen Grossman; Keli Song; Mithun Khattar; Kristina Xega; Xingyue He; James M. Gavin; Hisashi Imaichi; James J. Garnsey; Erik Koenig; Hongru Zhang; Zhen Lu; Pooja Shah; Yu Fu; Michael A. Milhollen; Beryl A. Hatton; Jessica Riceberg; Vaishali Shinde; Cong Li; James Minissale; Xiaofeng Yang; Dylan England; Richard A. Klingh...; Steve Langston; Katherine Galvin; Gary Shapiro; Sai M. Pulukuri; Serge Y. Fuchs; Dennis Huszar
• Keywords: Ex vivo; Priming (agriculture); Tumor Antigen

TAK-981, a first-in-class small-molecule SUMOylation inhibitor, activates type I interferon signaling to promote antitumor immune responses in mice.